# Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study

Source: https://onco.cc/trials/nct07150416/  
OnCo record `nct07150416` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in lung cancer, run by The First Affiliated Hospital of Guangzhou Medical University, not yet recruiting.

## Summary

Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study is a phase 2, interventional study registered as NCT07150416 by The First Affiliated Hospital of Guangzhou Medical University, with a registry enrolment figure of 38 participants, started 2025-10-01 and due to reach its primary completion in 2026-12-01. Interventions recorded: Recombinant Human Ad-p53 Injection. Conditions listed: Multiple Pulmonary Ground-Glass Nodules; Lung Neoplasms; Precancerous Conditions. Primary outcome: Objective Response Rate (ORR). Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07150416
- Phase: 2
- Setting: A Single-Arm Clinical Study of Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection (Gendicine) for Treatment of Multiple Ground-Glass Lung Nodules
- Sponsor: The First Affiliated Hospital of Guangzhou Medical University
- Enrolled: 38

## Sources

- ClinicalTrials.gov NCT07150416: https://clinicaltrials.gov/study/NCT07150416

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07150416.json